✦ LIBER ✦

Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study

✍ Scribed by Prasher, V. P.; Sachdeva, N.; Adams, C.; Haque, M. S.

Book ID: 118759001
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 68 KB
Volume: 28
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.3821

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rivastigmine in the treatment of dementi

Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome

✍ V. P. Prasher; N. Fung; C. Adams 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 2 views

Use of rivastigmine transdermal patch in

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease

✍ Winblad, Bengt; Machado, João Carlos 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 806 KB

Drug Profile: Transdermal Rivastigmine P

Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

✍ Murat Emre; Roberto Bernabei; Rafael Blesa; Roger Bullock; Luis Cunha; Hugo Dani 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

Season of birth: dementia in Alzheimer's

Season of birth: dementia in Alzheimer's disease in adults with Down Syndrome

✍ V. P. Prasher; H. M. Kapadia; M. S. Haque 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

Weight loss in adults with Down syndrome

Weight loss in adults with Down syndrome and with dementia in Alzheimer’s disease

✍ V.P Prasher; T Metseagharun; S Haque 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Review of donepezil, rivastigmine, galan

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

✍ V. P. Prasher 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability